Frontiers in Oncology (Nov 2021)
Cancer of Pharyngoesophageal Junction: A Different Subtype From Hypopharyngeal and Cervical Esophageal Cancer?
- Xiaoyu Li,
- Xiaoyu Li,
- Dashan Ai,
- Dashan Ai,
- Dashan Ai,
- Yun Chen,
- Yun Chen,
- Yun Chen,
- Qi Liu,
- Qi Liu,
- Qi Liu,
- Jiaying Deng,
- Jiaying Deng,
- Jiaying Deng,
- Hongcheng Zhu,
- Hongcheng Zhu,
- Hongcheng Zhu,
- Ying Wang,
- Yue Wan,
- Yue Xie,
- Yanan Chen,
- Weiwei Chen,
- Weiwei Chen,
- Weiwei Chen,
- Jianhong Fan,
- Xiaoshen Wang,
- Xiaoshen Wang,
- Xiaoshen Wang,
- Xueguan Lu,
- Xueguan Lu,
- Xueguan Lu,
- Hongmei Ying,
- Hongmei Ying,
- Hongmei Ying,
- Xiayun He,
- Xiayun He,
- Xiayun He,
- Chaosu Hu,
- Chaosu Hu,
- Chaosu Hu,
- Kuaile Zhao,
- Kuaile Zhao,
- Kuaile Zhao
Affiliations
- Xiaoyu Li
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Xiaoyu Li
- Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China
- Dashan Ai
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Dashan Ai
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Dashan Ai
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Yun Chen
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Yun Chen
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Yun Chen
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Qi Liu
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Qi Liu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Qi Liu
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Jiaying Deng
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Jiaying Deng
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Jiaying Deng
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Hongcheng Zhu
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Hongcheng Zhu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Hongcheng Zhu
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Ying Wang
- Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China
- Yue Wan
- Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China
- Yue Xie
- Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China
- Yanan Chen
- Department of Oncology, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, China
- Weiwei Chen
- Department of Radiation Oncology, Yancheng Third People’s Hospital, Yancheng, China
- Weiwei Chen
- Department of Radiation Oncology, The Affiliated Yancheng Hospital of Southeast University Medical College, Yancheng, China
- Weiwei Chen
- Department of Radiation Oncology, The Sixth Affiliated Hospital of Nantong University, Nantong, China
- Jianhong Fan
- Department of Gynaecology, Renhe Hospital, Shanghai, China
- Xiaoshen Wang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Xiaoshen Wang
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Xiaoshen Wang
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Xueguan Lu
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Xueguan Lu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Xueguan Lu
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Hongmei Ying
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Hongmei Ying
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Hongmei Ying
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Xiayun He
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Xiayun He
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Xiayun He
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Chaosu Hu
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Chaosu Hu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Chaosu Hu
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- Kuaile Zhao
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Kuaile Zhao
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Kuaile Zhao
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
- DOI
- https://doi.org/10.3389/fonc.2021.710245
- Journal volume & issue
-
Vol. 11
Abstract
BackgroundSquamous cell cancers in the hypopharynx (HP) and cervical esophagus (CE) are different diseases with different staging systems and treatment approaches. Pharyngoesophageal junction (PEJ) tumor involves both the hypopharynx and the cervical esophagus simultaneously, but few reports focused on PEJ tumors. This study aimed to clarify clinical characteristics and the treatment approaches of PEJ tumors.Patients and MethodsA total of 222 patients with squamous cell carcinoma in the HP, PEJ, and CE were collected between January 2008 and June 2018 in Fudan University Shanghai Cancer Center. We compared different lymph node metastatic patterns of three diseases above and the survival of different tumor locations, different lymph node metastasis, and different radiotherapy approaches.ResultsFor HP, PEJ, and CE cancer, the upper and middle cervical lymph node metastatic rates were 85.7%, 47.1%, and 5.8%, respectively; the lower cervical lymph node metastatic rates were 36.7%, 42.9%, and 35.0%, respectively; and the mediastinal lymph node metastatic rates were 2.0%, 72.9%, and 80.6%, respectively. The 3-year overall survival rates were 69.5% in the HP group, 52.0% in the PEJ group, and 69.6% in the CE group (p = 0.024). No survival differences were found between the involved-field-irradiation and elective-node-irradiation subgroups among PEJ tumors (p = 0.717 for OS and p = 0.454 for PFS, respectively).ConclusionHP cancers had a high prevalence in all cervical lymph node metastases, while CE cancers had a lower prevalence in the cervical and mediastinal lymph node metastases. PEJ cancer had the combined metastatic patterns of both HP and CE cancers. Involved field irradiation was feasible in chemoradiotherapy for PEJ cancers.
Keywords
